Wells Fargo Maintains Equal-Weight on Pfizer, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Equal-Weight rating on Pfizer (NYSE:PFE) and raises the price target from $28 to $30.
July 31, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Equal-Weight rating on Pfizer and raises the price target from $28 to $30.
The raised price target from $28 to $30 by Wells Fargo indicates a positive outlook on Pfizer's stock, which could lead to a short-term increase in its stock price. However, the Equal-Weight rating suggests a neutral stance overall.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100